Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review

Abstract

SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.

Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19: A Meta-Analysis and Systematic Review

“…Much of the concern involving SARS-COV-2 and ACEi/ARBs revolves around RAAS signaling imbalance causing inflammation due to ATR1 activation. Studies performed by Hayiroglu et al [14], Gormez et al [15], and Al-Samkari et al [16] have revealed a linear relationship with inflammatory markers and severity of illness. Therefore, potential treatment targets for this virus may revolve around limiting RAAS activation.…”

Prognosis and hematological findings in patients with COVID-19 in an Amazonian population of Peru

“…It can be seen that in other parameters such as the neutrophil-lymphocyte ratio (RN / L), fibrinogen among others, they were higher in the population that died compared to the one that survived. Elevated fibrinogen level has been considered an epiphenomenon of pulmonary edema rather than activation of coagulation in affected patients(24). Platelet values, red cell distribution width with standard deviation (RDW-SD), and D-dimer were statistically similar in both groups.…”

Aprotinin ‐ a new multi-target drug candidate or "magic shotgun" for the therapy of COVID‐19

“…In addition, D-dimer is commonly used to diagnose or rule out thrombotic events such as deep vein thrombosis or pulmonary embolism. [19][20][21][22].…”